美康生物(300439) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 399,447,767.69, a decrease of 12.71% year-over-year[5] - Net profit attributable to shareholders was CNY 3,700,056.84, down 91.94% compared to the same period last year[5] - Net profit excluding non-recurring items was CNY 1,182,138.59, a decline of 97.25% year-over-year[5] - Total operating revenue decreased to ¥1,135,669,290.81 from ¥1,406,709,821.37, a decline of approximately 19.3%[23] - Operating profit fell to ¥54,101,653.44 from ¥250,212,726.27, representing a decrease of approximately 78.4%[24] - Net profit decreased to ¥58,893,569.05 from ¥223,329,538.72, a decline of around 73.7%[24] - Earnings per share dropped to ¥0.1576 from ¥0.5844, a decrease of approximately 73.0%[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,655,246,461.86, a decrease of 1.35% from the previous year[5] - The total non-current assets decreased from ¥1,880,920,162.34 to ¥1,775,350,820.43, representing a decline of about 5.6%[20] - The company’s total current liabilities decreased from ¥667,437,831.62 to ¥602,922,198.57, a decline of approximately 9.7%[20] - Total liabilities decreased to ¥706,758,428.14 from ¥771,646,162.98, a decline of approximately 8.4%[21] - The company’s total equity attributable to shareholders was CNY 2,955,784,542.29, an increase of 0.54% from the previous year[5] - Total equity increased to ¥2,948,488,033.72 from ¥2,933,468,343.82, an increase of about 0.5%[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 144,977,744.95, an increase of 32.96%[10] - Cash flow from operating activities for the current period is 144,977,744.95, an increase from 109,039,623.15 in the previous period[25] - Total cash inflow from investment activities is 723,164,208.45, up from 479,909,809.39 in the previous period[25] - Net cash flow from investment activities is -150,217,872.40, an improvement from -393,618,233.08 in the previous period[25] - Cash flow from financing activities shows a net outflow of -90,497,945.04, compared to -78,095,542.21 in the previous period[26] - The ending balance of cash and cash equivalents is 630,389,667.97, compared to 590,804,894.43 in the previous period[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,895[11] - The number of shares held by the top shareholder, Zou Bingde, is 108,897,635, representing a 28.34% ownership stake[14] - The company has a total of 91,986,764 restricted shares at the end of the period, down from 92,036,764 at the beginning, indicating a slight reduction in restricted shares[17] Other Financial Metrics - The weighted average return on equity was 0.13%, down 1.50% from the previous year[5] - The company reported a significant decrease in financial expenses by 71.08% due to interest income from structured deposits[9] - Deferred income increased to ¥27,170,000.04 from ¥17,020,000.02, an increase of about 59.8%[21] - Research and development expenses decreased to ¥103,113,005.51 from ¥114,751,323.89, a decline of approximately 10.2%[24] - Other comprehensive income after tax increased to ¥1,261,533.54 from -¥4,248,904.58, a significant improvement[24]